<DOC>
	<DOCNO>NCT01114828</DOCNO>
	<brief_summary>OPC-41061 3.75 mg/day 7.5 mg/day orally administer daily 7 day cirrhosis patient ascites despite receive treatment conventional diuretic pharmacodynamics , pharmacokinetics , efficacy , safety investigate .</brief_summary>
	<brief_title>A Study Investigate Pharmacodynamics Pharmacokinetics OPC-41061 Patients With Hepatic Edema</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients judge cirrhosis base previous image diagnosis ( Definition cirrhosis include patient collateral circulation due chronic hepatic impairment ) Patients ascites dose exist diuretic increase due risk adverse drug reaction electrolyte abnormality , sufficient therapeutic effect obtain exist diuretic Patients receive oral combination therapy loop diuretic antialdosterone agent least 7 day prior receipt informed consent , dose combination either loop diuretic equivalent furosemide 40 mg/day high plus spironolactone 25 mg/day high , loop diuretic equivalent furosemide 20 mg/day high plus spironolactone 50 mg/day high Patients hospitalize hospitalized trial Age 20 80 year inclusive Patients capable give informed consent Patients , together partner , agree use appropriate method contraception 4 week final trial drug administration Patients follow complication symptom : Hepatic encephalopathy ( hepatic coma grade 2 high ) Hepatocellular carcinoma imagingdiagnosed vascular infiltration trunk primary branch portal vein , inferior vena cava , trunk hepatic vein Endoscopic finding screen examination within 30 day prior screen examination indicate need new therapy esophageal gastric varix trial period Repeated hemorrhoidal bleeding due rectal varicose vein within 30 day prior informed consent Heart failure ( New York Heart Association Class III IV ) Anuria Impaired urination due urinary tract stricture , urinary calculus , tumor urinary tract , cause Patients history follow disorder : Cerebrovascular disorder within 30 day prior informed consent Hypersensitivity idiosyncratic reaction benzazepine derivative ( mozavaptan hydrochloride benazepril hydrochloride ) `` Morbidly obese patient body mass index ( BMI : body weight ( kg ) /height ( ) 2 ) exceed 35 Patients sit systolic blood pressure low 90 mm Hg Patients follow abnormal clinical laboratory value time screen examination : Hemoglobin low 8.0 g/dL , total bilirubin high 4.0 mg/dL , serum creatinine high 2.0 mg/dL , serum sodium high 147 mEq/L , serum potassium high 5.5 mEq/L Patients unable take oral medication Female patient pregnant , possibly pregnant , breastfeeding , plan become pregnant Patients use albumin preparation ( therapeutic agent hypoalbuminemia ) blood product contain albumin within 7 day prior informed consent Patients receive investigational drug OPC41061 within 30 day prior informed consent Patients previously receive OPC41061 Any patient , opinion principle investigator subinvestigator , inappropriate participation trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>ascites</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>OPC-41061</keyword>
</DOC>